Answers are grounded in this paper and cite their sources.
Background Esophageal squamous cell carcinoma (ESCC) remains a major global health burden, with limited response rates to neoadjuvant immunochemotherapy (NICT). Accurate preoperative prediction of pathological complete response (pCR) may enable optimized treatment decisions. This study aimed to develop and validate an end-to-end deep learning–habitat fusion model integrating longitudinal CT images to predict pCR. Methods A total of 529 ESCC patients from two centers who received NICT followed by surgery were retrospectively analyzed. Longitudinal contrast-enhanced CT images were processed for tumor segmentation and habitat clustering using voxel-wise radiomic features. A transformer-based model (Habitat-Former) was designed to fuse temporal CT and habitat information for pCR prediction. Model performance was evaluated using area under the ROC curve (AUC). Prognostic value was assessed with Kaplan–Meier analyses. scRNA-seq was performed on 11 post-treatment tumor samples to explore immune-cell subpopulations and transcriptomic patterns potentially associated with pathological response. Results Habitat-Former achieved numerically higher performance across all cohorts, with AUCs of 0.917, 0.831, and 0.816 in the training cohort, internal test cohort, and external test cohort, respectively. In exploratory survival analyses among patients with complete follow-up, model-defined groups differed in PFS and OS in the training cohort ( P = 0.0076 and P = 0.037) but only in PFS in the internal test cohort ( P = 0.017). Exploratory scRNA-seq analysis of 11 post-treatment tumor samples identified candidate associations between model-derived imaging scores and myeloid-cell composition. Conclusions The proposed Habitat-Former model showed numerically favorable discrimination for pCR prediction in ESCC patients undergoing NICT and provided exploratory molecular correlates of treatment response in the tumor immune microenvironment. This model may serve as an adjunctive tool for preoperative response assessment and the development of imaging-driven biomarkers for immunotherapy response.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: